Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Journal Article (Journal Article)

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

Full Text

Duke Authors

Cited Authors

  • Muir, AJ; Gong, L; Johnson, SG; Lee, MTM; Williams, MS; Klein, TE; Caudle, KE; Nelson, DR; Clinical Pharmacogenetics Implementation Consortium (CPIC),

Published Date

  • February 2014

Published In

Volume / Issue

  • 95 / 2

Start / End Page

  • 141 - 146

PubMed ID

  • 24096968

Pubmed Central ID

  • PMC3904555

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1038/clpt.2013.203


  • eng

Conference Location

  • United States